- Price
- $2.19
- Day
- +1.86%
- Mkt Cap
- $441.34M
- 52W Range
- $1.15 – $3.47
- Volume
- 6.25M
- Beta
- 1.77
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript
Read full article
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update. “This quarter we made significant progress in expanding patient access to safer blood components around the globe,” said Vivek Jayaraman, Cerus' president and chief executive officer. “I'm particularly pleased with the performance of our INTERCEPT Fibrinogen Complex (IFC) franchise in the U.S. The value proposition for b.
Read full article
Cerus NASDAQ: CERS reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas.
Read full article
Amova Asset Management Americas Inc. reduced its stake in shares of Cerus Corporation (NASDAQ: CERS) by 4.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,516,606 shares of the biotechnology company's stock after selling 193,353 shares during
Read full article
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.
Read full article